Sol-Gel Technologies
Sol-Gel Technologies is a clinical-stage Israeli dermatology company (NASDAQ: SLGL) developing topical microencapsulation-based drugs for rare and common skin conditions, including lead Phase 3 candidate SGT-610 for Gorlin syndrome and FDA-approved TWYNEO and EPSOLAY licensed to Galderma.
- Company typePublic
- Founded1997
- HeadquartersNes Ziyyona, Israel
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Sol-Gel Technologies does
Sol-Gel Technologies Ltd. is a clinical-stage and commercial dermatology company headquartered in Ness Ziona, Israel, and listed on NASDAQ under ticker SLGL. The company develops topical pharmaceutical products using a proprietary microencapsulation and formulation platform that enables novel local delivery while limiting systemic exposure. Its portfolio spans two FDA-approved marketed products — TWYNEO (tretinoin 0.1% / benzoyl peroxide 3% cream for acne vulgaris) and EPSOLAY (encapsulated benzoyl peroxide 5% cream for rosacea) — and two clinical-stage assets: SGT-610, a topical 2% patidegib gel in Phase 3 for prevention of new basal cell carcinoma lesions in Gorlin syndrome (with Orphan Drug and FDA Breakthrough Therapy designations); and SGT-210, a topical erlotinib platform being evaluated in feasibility studies after a December 2025 Darier disease failure. Sol-Gel holds EU and FDA Orphan Drug status on patidegib and Breakthrough Therapy designation on the same molecule.
The company operates a capital-light, asset-light business model with 51–100 employees and no commercial sales force. Revenue is generated through licensing royalties and milestone payments from established pharmaceutical partners — primarily Galderma, which holds US commercialization rights to TWYNEO and EPSOLAY, plus Mayne Pharma and Search Light Pharma for Canada. Q1 2026 reported revenue was $108K versus $900K consensus, indicating that the current licensing streams remain de minimis. The controlling shareholder is Arkin Dermatology (Arkin family), with Chairman/CEO Moshe Arkin leading a small executive team and a board that includes former Perrigo and Given Imaging CFOs. The company is funded to advance SGT-610 through its pivotal Phase 3 readout expected in Q4 2026.
Sol-Gel Technologies firmographics
Firmographics- Name
- Sol-Gel Technologies
- Legal name
- SOL-GEL Technologies Ltd.
- Website
- https://sol-gel.com
- Company type
- Public
- Founded year
- 1997
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Sol-Gel Technologies is a clinical-stage Israeli dermatology company (NASDAQ: SLGL) developing topical microencapsulation-based drugs for rare and common skin conditions, including lead Phase 3 candidate SGT-610 for Gorlin syndrome and FDA-approved TWYNEO and EPSOLAY licensed to Galderma.
- Ownership category
- akta.pro rank
Sol-Gel Technologies industry classification
Industry- Product category
- Specialty Dermatology Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Dermatology Specialty Pharmaceuticals (HLAIACAL)
- akta.pro secondary industries
- Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK), Dermatology & Topical Skin Treatments (HLAIADAE)
Keywords
Where Sol-Gel Technologies is headquartered
LocationHeadquarters
- HQ city
- Nes Ziyyona
- HQ country
- Israel
- HQ region
- Middle East
Offices1 record
Markets served
Sol-Gel Technologies business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Licensing Royalties - TWYNEO: TWYNEO is licensed to Galderma for US commercialization. Sol-Gel receives royalties on sales.
- Licensing Royalties - EPSOLAY: EPSOLAY is licensed to Galderma for US commercialization. Sol-Gel receives royalties on sales.
- Development Milestones: Potential milestone payments from licensing partners tied to development and regulatory milestones.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels3 records
Sol-Gel Technologies product offering
Product offeringCore offering
Sol-Gel Technologies develops and licenses topical dermatological pharmaceutical products, including two FDA-approved products (TWYNEO for acne vulgaris and EPSOLAY for inflammatory lesions of rosacea) and a pipeline targeting rare skin conditions such as Gorlin syndrome. The company leverages proprietary microencapsulation technology to create novel topical formulations and out-licenses commercialization rights to established dermatology companies including Galderma.
Product overview
Sol-Gel Technologies is a dermatology company developing a portfolio of topical pharmaceutical products spanning both rare skin conditions and common dermatological indications. The pipeline includes SGT-610 (patidegib gel, Phase III) and SGT-210 (topical erlotinib, Phase I completed) as investigational candidates targeting Gorlin syndrome, high-frequency BCC, and keratinization disorders. The commercial portfolio consists of two FDA-approved products licensed to Galderma: TWYNEO (tretinoin and benzoyl peroxide cream for acne) and EPSOLAY (encapsulated benzoyl peroxide cream for rosacea). The company leverages proprietary microencapsulation technology to develop topical formulations that enhance drug delivery and minimize systemic exposure.
Differentiator
Problem solved
Functional benefit
Brands
- TWYNEO: Topical treatment for acne vulgaris - first and only FDA-approved fixed-dose combination of tretinoin and benzoyl peroxide (BPO) for adults and pediatric patients 9 years and older.
- EPSOLAY
Products and services
- TWYNEO The first and only FDA-approved fixed-dose combination of tretinoin (0.1%) and benzoyl peroxide (3%) for the topical treatment of acne vulgaris in adults and pediatric patients 9 years of age and older. Marketed in the US by Galderma and planned for availability in Canada.
- EPSOLAY The first and only FDA-approved encapsulated benzoyl peroxide (5%) topical cream for the treatment of inflammatory lesions of rosacea in adults. Marketed in the US and planned for availability in Canada.
- SGT-610 A topically applied 2% patidegib gel, Sol-Gel's lead pipeline candidate for the prevention of new basal cell carcinoma lesions in patients with Gorlin syndrome. A topical hedgehog pathway inhibitor leveraging a unique formulation with minimal risk for systemic adverse events; granted FDA Orphan Drug and Breakthrough Therapy designations.
- SGT-210 A topical erlotinib drug candidate platform designed to enable local EGFR inhibition while limiting systemic exposure. Used in compassionate care for Olmsted syndrome.
Companies that use Sol-Gel Technologies
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles1 record
Sol-Gel Technologies technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Sol-Gel Technologies partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core.
- Mayne PharmacoreTWYNEO will be available in Canada through Mayne Pharma, with planned launch in early 2024.
- GaldermacoreTWYNEO and EPSOLAY are licensed to Galderma for US commercialization. Galderma handles all marketing, distribution and sales activities for these products in the US market. This is Sol-Gel's primary commercial partnership for its approved products.
- Search Light PharmacoreTWYNEO will be available in Canada through Search Light Pharma partnership.
- Gorlin Syndrome AlliancecoreSol-Gel partnered with the Gorlin Syndrome Alliance to support, educate, and empower patients and their loved ones as they navigate this condition. This patient advocacy partnership is important for clinical trial recruitment and disease awareness.
Scale indicators8 records
Recent moves6 records
Expansion highlights5 records
Sol-Gel Technologies competitors and assessment
Company assessmentDirect peers
- Arcutis Biotherapeutics: Arcutis is a US-listed dermatology-focused biopharma developing and commercializing topical treatments for inflammatory skin diseases. It overlaps directly with Sol-Gel in topical formulation R&D, dermatology pipeline strategy, and similar scale/go-to-market profile.
- Verrica Pharmaceuticals: Verrica is a US dermatology specialty pharma focused on topical therapies for skin diseases including molluscum and common warts. It is comparable to Sol-Gel in being a small-cap, US-listed dermatology company with prescription topical products and similar capitalization range.
- Aclaris Therapeutics: Aclaris is a clinical-stage dermatology biopharmaceutical company developing immunomodulatory and topical therapies for skin and immune-mediated diseases. It matches Sol-Gel as a small-cap, dermatology-focused innovator with both approved and pipeline assets.
- Dermavant Sciences: Dermavant is a Roivant-backed dermatology company developing topical therapies for inflammatory skin conditions. It is comparable to Sol-Gel in its topical dermatology pipeline focus and similar stage of commercialization.
- Biofrontera: Biofrontera is a dermatology company specializing in topical photodynamic therapies and prescription skin treatments. It overlaps with Sol-Gel in the prescription topical dermatology category and similar small/mid-cap profile.
Broad incumbents
- Galderma: Galderma is the world's largest pure-play dermatology company and Sol-Gel's key US commercialization partner for TWYNEO and EPSOLAY. It is comparable as a broad dermatology incumbent with overlapping topical product portfolios and significantly greater scale.
- Almirall: Almirall is a European dermatology-focused pharmaceutical company with a broad prescription dermatology portfolio. It is comparable to Sol-Gel as a dermatology-specialist incumbent with topical and systemic treatments across multiple indications.
Emerging players
- Novan: Novan is a clinical-stage dermatology company developing nitric oxide-based topical therapies for skin diseases. It is comparable to Sol-Gel as a small, emerging topical dermatology innovator with pipeline-stage assets.
Others
- Anacor Pharmaceuticals: Anacor was a US dermatology-focused biopharma (acquired by Pfizer in 2016) that developed boron-based topical therapies. It is included as a historical comparable showing the typical exit pathway for small-cap topical dermatology innovators like Sol-Gel.
- Cassiopea: Cassiopea was a dermatology specialty company (acquired by Cosmo Pharmaceuticals) that developed prescription topical treatments including for acne. It is included as a historical small-cap dermatology peer and acquisition comparable for Sol-Gel.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
Sol-Gel Technologies social profiles
Digital presenceSol-Gel Technologies compliance and trust
Trust signalCompliance2 records
Sol-Gel Technologies financial estimates
Financial estimateRevenue estimate
Valuation estimate
Sol-Gel Technologies leadership team
Management profileNumber of profiles
Profiles11 records
Sol-Gel Technologies funding detail
Funding detailFunding overview
Funding rounds2 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Sol-Gel Technologies M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Sol-Gel Technologies
What does Sol-Gel Technologies do?
Sol-Gel Technologies develops and licenses topical dermatological pharmaceutical products, including two FDA-approved products (TWYNEO for acne vulgaris and EPSOLAY for inflammatory lesions of rosacea) and a pipeline targeting rare skin conditions such as Gorlin syndrome. The company leverages proprietary microencapsulation technology to create novel topical formulations and out-licenses commercialization rights to established dermatology companies including Galderma.
Is Sol-Gel Technologies a public or private company?
Sol-Gel Technologies is a public company. It is classified as public and is currently operating.
When was Sol-Gel Technologies founded?
Sol-Gel Technologies was founded in 1997. It employs 11 to 50 people.
Where is Sol-Gel Technologies based?
Sol-Gel Technologies is headquartered in Nes Ziyyona, Israel, in the Middle East region.
How does Sol-Gel Technologies make money?
Three revenue lines are on record. Licensing Royalties - TWYNEO is the primary driver. The others are licensing Royalties - EPSOLAY and development Milestones.
Who are Sol-Gel Technologies's main competitors?
Direct peers on record are Arcutis Biotherapeutics, Verrica Pharmaceuticals, Aclaris Therapeutics, Dermavant Sciences and Biofrontera. Broad incumbents are Galderma and Almirall. Novan is listed as an emerging player. Others are Anacor Pharmaceuticals and Cassiopea.
Does Sol-Gel Technologies have an API?
No public API is recorded for Sol-Gel Technologies.
What industry is Sol-Gel Technologies in?
Sol-Gel Technologies's product category is Specialty Dermatology Pharmaceuticals. Its primary akta.pro industry code is HLAIACAL, Dermatology Specialty Pharmaceuticals, with a secondary code of HLAIAAAK, Dermatology & Aesthetics Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2833.